World News | J&J-HIV VACCINE-STUDY J&J: Potential HIV Vaccine Falls Short in Mid-stage Study
Get latest articles and stories on World at LatestLY. A potential HIV vaccine being developed by Johnson & Johnson did not provide protection against the virus in a mid-stage study, the drugmaker said Tuesday.
Washington, Aug 31 (AP) A potential HIV vaccine being developed by Johnson & Johnson did not provide protection against the virus in a mid-stage study, the drugmaker said Tuesday.
J&J plans to end that study, which involved young women in sub-Saharan Africa. But researchers will continue a separate, late-stage trial involving a different composition of the vaccine in men and transgender people.
The study in sub-Saharan Africa involved about 2,600 women who were deemed to be at high risk of acquiring HIV, which causes AIDS. Participants were randomly selected to receive either the vaccine or a placebo, and researchers found that the vaccine was only 25% effective at preventing HIV.
“HIV is a unique and complex virus that has long posed unprecedented challenges for vaccine development because of its ability to attack, hijack and evade the human immune system,” J&J Chief Scientific Officer Dr Paul Stoffels said in a statement.
Also Read | Saudi Arabia: Drone Attack on Abha Airport Wounds 8, Damages Civilian Plane.
J&J said its other study of the potential vaccine is being conducted in Europe and the Americas, where different strains of HIV are circulating.
New Brunswick, New Jersey-based Johnson & Johnson also makes one of the three vaccines approved by US regulators for the prevention of COVID-19. J&J also is developing vaccines for sepsis and respiratory syncytial virus. (AP)
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)